rd14-01 cell
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 5, 2022 (NCT05444322)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase transmembrane receptor ROR1Immunity, passive
ROR1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05638828 | Early Phase 1 (Phase 1) | Dec 1, 2022 | Peking University |
| NCT05444322 | Early Phase 1 (Phase 1) | Jul 5, 2022 | Zhejiang University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1